An author of medical thrillers, and one of the original members
of the International Thriller Writers Association, Dr. Nelson
Erlick has a wide range of experience in medical/surgical specialty
practice and in analyzing some of the most controversial and
complicated medical technologies of our time.
A retired Board Certified Podiatric Surgeon and award winning
researcher, Dr. Erlick, holds a Doctor of Podiatric Medicine
(DPM) from the Pennsylvania College of Podiatric Medicine, an
MS in Biology from Drexel University, and a BA in Biochemistry
and Natural Science from the University of Pennsylvania. He
has twice won the top award in podiatry (William Stickel Gold
Medal) for original research on topics in wound healing and
diabetes, respectively, as well as the top research award for
podiatric residents (O'Neal Jones and Feldman) for developing
a new skeletal radiographic measurement technique.
Following eleven years of private practice,
Dr. Erlick served as the Senior Health Technology Analyst
at ECRI, an internationally renowned medical technology "think tank", where he researched,
analyzed, and wrote comprehensive, precedent-setting assessments
on controversial topics including: high-dose chemotherapy with
bone marrow transplants for the treatment of breast cancer,
ovarian cancer, and lung cancers, as well as innovative developments
in biotechnology, laser therapy, electrical stimulation for
wound healing, and pain management. In particular, one of his
assessments demonstrated that regimens using high-dose chemotherapy
with bone marrow (or blood cell) transplantation for women with
breast cancer were ineffective--five years before the oncology
community came to the same conclusion. Agencies of the U.S.
government, including the Health Care Finance Administration
(Medicare), various state regulatory agencies, and major
health insurers have used Dr. Erlick's assessment reports to
determine whether medical innovations are safe and effective
for the public.
Subsequently, Dr. Erlick worked in the pharmaceutical industry,
first as a Senior Clinical Writer, responsible for interpreting
and writing key clinical and statistical documents for submission
of new products, including antibiotics, to the Food and Drug
Administration, and then as a Manager of Medical Information
and Technical Writing where he participated in the design of
clinical studies for pain management. Currently, he serves as
Medical Director at a renowned medical communications firm in
the Philadelphia area, where he writes articles and designs
meta-analyses on critical studies centering on emerging agents
for the treatment of cancer.
His first novel, the critically-acclaimed medical thriller GermLine (Forge
2003), received praise from leaders in the scientific community
(including W. French Anderson, MD, the "Father of Gene Therapy",
and J. Craig Venter, PhD, President of the Center for the
Advancement of Genomics), literary critics (including Kirkus
Reviews, Library Journal, The Philadelphia Inquirer), and noted
novelists (Douglas Preston, Greg Cox).
The Xeno Solution (Forge, October
2005) is Dr. Erlick's second novel and has received advanced praise
from renowned novelists including Michael Palmer, John Lescroart,
and David Dun.
with Nelson Erlick
the Backstory of "The Xeno Solution"